Recordati Group, with Headquarters in Milan, Italy, is a modern and dynamic company within the pharmaceutical industry with 4,000 employees, international and mainly dedicated to research, development, production and marketing of essential pharmaceuticals. It was founded in 1926 and began its internationalization in Spain, as the first country, in 1995 successfully maintaining its characteristic success and quality. It has continued to expand by acquiring the company Orphan Europe (orphan drugs) in 2007.
Recordati has been listed on the Italian Stock Exchange since 1984, with a turnover of € 941.6 million in 2013.
At the end of 2013, Recordati decided to acquire 100% shares of Laboratorios Casen-Fleet SLU with the aim of strengthening its investments and presence in the Spanish market, obtaining a business model of high growth in various therapeutic areas specializing in prescription and over-the-counter drugs.
Thanks to this strategy, Casen Recordati SL has been born as a company specializing in the areas of Cardiology, Gastroenterology, Pediatrics, Urology and Gynecology, with drugs leadering in lipids, oral rehydration, intestinal evacuants, laxatives and women’s care, among others.
Casen Recordati SL, with strategic operations center in Utebo, Zaragoza, and commercial headquarters in Madrid, is provided with its own production plant (first class infrastructure in a productive technical level) and a department of research and development on new products where not only essential drugs and pharmaceuticals are produced but also nutritional supplements, among others. Casen Recordati S. L. supports health and pharmaceutical professionals and clients, always committed to improving the quality of life of patients and providing quality service. This allows to bringing solutions to new and diverse diseases thanks to the experience acquired from decades of research and commitment to healthcare professionals and patients.